<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04446871</url>
  </required_header>
  <id_info>
    <org_study_id>HCG/CEI-0252/17</org_study_id>
    <nct_id>NCT04446871</nct_id>
  </id_info>
  <brief_title>Methylene Blue in Early Septic Shock</brief_title>
  <acronym>SHOCKEM-Blue</acronym>
  <official_title>Early Use of Methylene Blue in Patients With Septic Shock: a Pilot Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Civil de Guadalajara</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Civil de Guadalajara</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Septic shock is a subset of sepsis characterized by a decrease in vascular tone, which&#xD;
      contributes to impaired regional blood flow distribution, and leads to organic failure.&#xD;
      Besides intravenous fluids and adequate antimicrobial therapy, patients with septic shock&#xD;
      require vasopressor support, which can lead to many adverse effects, therefore,&#xD;
      non-vasopressor agents that can improve hemodynamic status are needed. In this randomized&#xD;
      controlled-study, the investigators will address the efficacy and safety of infusion with&#xD;
      methylene blue in patients with septic shock.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Unlike sepsis, septic shock mortality is not declining for the last decade, and is still&#xD;
      around 40%. After restoring intravascular volume, many patients need vasopressor agents to&#xD;
      maintain arterial blood pressure, which leads to improvement of perfusion at some vascular&#xD;
      beds, however some organs may suffer from maldistribution of blood flow. These changes of&#xD;
      regional blood flow may compromise oxygen delivery and perpetuate the inflammation and tissue&#xD;
      damage associated with the state of shock.&#xD;
&#xD;
      One of the main mechanisms of vasodilation after inflammatory insults, is the activation of&#xD;
      the inducible isoform of Nitric Oxide Synthase (iNOS), and the subsequent increase in the&#xD;
      levels of nitric oxide, which even reduces the response to vasoconstrictor agents. Methylene&#xD;
      blue (MB) is a selective inhibitor of iNOS, which has been used successfully in patients with&#xD;
      post-cardiopulmonary bypass associated vasoplegia, however, the evidence of the use of MB in&#xD;
      septic shock patients is limited to case reports, observational and small studies. In this&#xD;
      randomized controlled trial, the investigators will compare the efficacy and safety outcomes&#xD;
      of repeated doses of MB in patients with septic shock.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 17, 2017</start_date>
  <completion_date type="Actual">January 25, 2021</completion_date>
  <primary_completion_date type="Actual">December 10, 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Vasopressor requirement</measure>
    <time_frame>7 days</time_frame>
    <description>Total time in hours of vasopressor requirement</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to lactate normalization</measure>
    <time_frame>7 days</time_frame>
    <description>Time in hours until lactate is &lt;2 mmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay in intensive care unit</measure>
    <time_frame>28 days</time_frame>
    <description>Time in days until ICU discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensive care unit mortality</measure>
    <time_frame>28 days</time_frame>
    <description>Mortality in intensive care unit</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in pulmonary function after treatment</measure>
    <time_frame>7 days</time_frame>
    <description>Change in P/F index after three doses of methylene blue</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">91</enrollment>
  <condition>Septic Shock</condition>
  <arm_group>
    <arm_group_label>Standard care</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Methylene blue</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Methylene blue</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.9% sodium chloride</intervention_name>
    <description>Intravenous infusion of 500 cc of 0.9% sodium chloride solution for 6 h, once a day for a total of 3 doses.</description>
    <arm_group_label>Standard care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylene Blue</intervention_name>
    <description>Intravenous infusion of 100 mg methylene blue in 500 cc of 0.9% sodium chloride solution for 6 h, once a day for a total of 3 doses.</description>
    <arm_group_label>Methylene blue</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Septic shock diagnosis, according to 2016 Surviving Sepsis Campaign Guidelines.&#xD;
&#xD;
          -  Prior adequate fluid resuscitation according to dynamic predictors of volume&#xD;
             responsiveness.&#xD;
&#xD;
          -  More than 6 h and less than 24 h of norepinephrine requirement to maintain a mean&#xD;
             arterial pressure ≥65 mmHg.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt; 18 years.&#xD;
&#xD;
          -  Pregnancy.&#xD;
&#xD;
          -  Not expected to survive 48 hours.&#xD;
&#xD;
          -  Presence or high suspicion of concurrent hemorrhagic, obstructive or hypovolemic&#xD;
             shock.&#xD;
&#xD;
          -  Personal or familiar history of glucose-6-phosphate dehydrogenase deficiency.&#xD;
&#xD;
          -  Allergic to methylene blue, phenothiazines, or food dyes.&#xD;
&#xD;
          -  Recent intake (4-weeks) of selective serotonin re-uptake inhibitors.&#xD;
&#xD;
          -  Refusal of the patient or decision maker to enroll in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Miguel Ibarra-Estrada, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Investigator</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Civil Fray Antonio Alcalde</name>
      <address>
        <city>Guadalajara</city>
        <zip>44280</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>June 22, 2020</study_first_submitted>
  <study_first_submitted_qc>June 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 25, 2020</study_first_posted>
  <last_update_submitted>April 12, 2021</last_update_submitted>
  <last_update_submitted_qc>April 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Civil de Guadalajara</investigator_affiliation>
    <investigator_full_name>Miguel Á Ibarra-Estrada</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>Septic shock</keyword>
  <keyword>Methylene blue</keyword>
  <keyword>Norepinephrine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock, Septic</mesh_term>
    <mesh_term>Shock</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylene Blue</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

